ClinicalTrials.gov
ClinicalTrials.gov Menu

Incidence of Delirium in Hip Fracture Patients Randomized to Regular Hypnotics vs Placebo

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00286936
Recruitment Status : Terminated (Slow inclusion resulting in premature termination due to logistics)
First Posted : February 6, 2006
Last Update Posted : August 30, 2011
Sponsor:
Collaborator:
IMK Fonden
Information provided by:
Hvidovre University Hospital

Brief Summary:
To examine the influence of regular hypnotic therapy on the incidence of delirium after hip fracture surgery

Condition or disease Intervention/treatment Phase
Hip Fracture Delirium Drug: Zolpidem Phase 4

Detailed Description:
Delirium is prevalent after hip fracture surgery. Delirium has been linked to postoperative sleep disturbances. Zolpidem is a non-benzodiazepine hypnotic that preserves REM sleep. The present study investigates the incidence of delirium in hip fracture patients randomized to Zolpidem treatment 5 mg vs placebo in the perioperative phase.

Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 96 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double
Primary Purpose: Prevention
Official Title: Incidence of Delirium in Hip Fracture Patients Randomized to Regular Hypnotics vs Placebo
Study Start Date : February 2004
Actual Study Completion Date : January 2007

Resource links provided by the National Library of Medicine





Primary Outcome Measures :
  1. Incidence and severity of postoperative delirium

Secondary Outcome Measures :
  1. Sleep quality
  2. mobilization
  3. loss of functional ability
  4. length of stay
  5. sedation
  6. nocturnal nursing events


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   70 Years and older   (Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Primary hip fracture, no substance abuse, no regular opioid, corticosteroid or benzodiazepine therapy, hepatic insufficiency, myastenia gravis, allergies to drug components

Exclusion Criteria:

  • Severe respiratory insufficiency

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00286936


Locations
Denmark
Hvidovre University Hospital
Hvidovre, Denmark, 2650
Sponsors and Collaborators
Hvidovre University Hospital
IMK Fonden
Investigators
Study Director: Nicolai B Foss, MD Hvidovre University Hospital

ClinicalTrials.gov Identifier: NCT00286936     History of Changes
Other Study ID Numbers: HHSG-RCT-05
First Posted: February 6, 2006    Key Record Dates
Last Update Posted: August 30, 2011
Last Verified: September 2006

Keywords provided by Hvidovre University Hospital:
Hip fracture
delirium
sleep disturbance
hypnotic

Additional relevant MeSH terms:
Fractures, Bone
Delirium
Hip Fractures
Wounds and Injuries
Confusion
Neurobehavioral Manifestations
Neurologic Manifestations
Nervous System Diseases
Signs and Symptoms
Neurocognitive Disorders
Mental Disorders
Femoral Fractures
Hip Injuries
Leg Injuries
Zolpidem
Hypnotics and Sedatives
Central Nervous System Depressants
Physiological Effects of Drugs
GABA-A Receptor Agonists
GABA Agonists
GABA Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action